Vanda Pharmaceuticals, Inc. (VNDA)
5.43
+0.09
(+1.69%)
USD |
NASDAQ |
Sep 04, 16:00
5.43
0.00 (0.00%)
After-Hours: 20:00
Vanda Pharmaceuticals Shareholders Equity (Quarterly) : 220.18M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 220.18M |
| March 31, 2026 | 280.76M |
| December 31, 2025 | 327.19M |
| September 30, 2025 | 466.00M |
| June 30, 2025 | 486.33M |
| March 31, 2025 | 511.42M |
| December 31, 2024 | 538.55M |
| September 30, 2024 | 541.22M |
| June 30, 2024 | 542.52M |
| March 31, 2024 | 544.00M |
| December 31, 2023 | 544.91M |
| September 30, 2023 | 543.10M |
| June 30, 2023 | 539.90M |
| March 31, 2023 | 535.74M |
| December 31, 2022 | 527.20M |
| September 30, 2022 | 515.66M |
| June 30, 2022 | 508.55M |
| March 31, 2022 | 502.12M |
| December 31, 2021 | 504.93M |
| September 30, 2021 | 493.32M |
| June 30, 2021 | 481.22M |
| March 31, 2021 | 467.63M |
| December 31, 2020 | 453.27M |
| September 30, 2020 | 440.57M |
| June 30, 2020 | 431.58M |
| Date | Value |
|---|---|
| March 31, 2020 | 416.39M |
| December 31, 2019 | 410.94M |
| September 30, 2019 | 400.91M |
| June 30, 2019 | 296.69M |
| March 31, 2019 | 278.40M |
| December 31, 2018 | 275.42M |
| September 30, 2018 | 261.42M |
| June 30, 2018 | 251.27M |
| March 31, 2018 | 241.14M |
| December 31, 2017 | 131.39M |
| September 30, 2017 | 130.47M |
| June 30, 2017 | 131.42M |
| March 31, 2017 | 128.14M |
| December 31, 2016 | 131.33M |
| September 30, 2016 | 129.16M |
| June 30, 2016 | 121.61M |
| March 31, 2016 | 123.01M |
| December 31, 2015 | 133.03M |
| September 30, 2015 | 145.94M |
| June 30, 2015 | 149.75M |
| March 31, 2015 | 152.47M |
| December 31, 2014 | 160.82M |
| September 30, 2014 | 1.063M |
| June 30, 2014 | 0.885M |
| March 31, 2014 | 20.98M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Protagonist Therapeutics, Inc. | 841.54M |
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Anika Therapeutics, Inc. | 137.28M |
| Savara, Inc. | 143.66M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 412.47M |
| Total Liabilities (Quarterly) | 192.28M |
| Debt to Equity Ratio | 0.1037 |
| Current Ratio | 1.612 |
| Net Debt Paydown Yield | -0.60% |